exceeding-commissioner.blogspot.com
Under the terms of the Adolor (NASDAQ:ADLR), of Exton, Pa., will receiv a $30 million upfront payment from Pfizer and the potentia to earnanother $232 million, contingent upon achieving undisclosed development and regulatory milestones. The most advancedr of two productsis ADL5859, which is in midstagew development as a treatment for inflammatoryy pain associated with rheumatoid arthritis and acute post-dentakl surgery pain. The company also plans to study ADL5859 in patientsa with diabetic peripheral neuropathyand osteoarthritis. Adolor expects to begin initial human clinicap testing of thesecond ADL5747, in the firs t quarter of 2008.
The company did not disclose the condition for which the new pain drug candidate willbe tested. Pfizer (NYSE: of New York, also agreec to pay Adolor $1.9 million for previous clinicaltrial expenses. The partnership callsx for Pfizer to secure regulatoryy approvals and handle commercialization of the products on aworldwidw basis. Pfizer and Adolor will share revenuew and expenses undera 60-4o0 percent split, respectively, in the United States.
Pfizer will fund developmeng activities and, if the products receivew regulatory approval, Adolor will receive royalties on net salesfrom
ليست هناك تعليقات:
إرسال تعليق